Repligen jumps on upbeat Q2 results, 2022 forecast raise

Repligen

02/08/2022 16:40

** Shares of Repligen Corp  RGEN.O  rise 13% to $240.23,
hitting their highest in nearly seven months
    ** RGEN beats Q2 revenue and profit estimates, driven by
strong demand for its monoclonal antibody and gene therapy
development products  urn:newsml:reuters.com:*:nGNXhhf7q
    ** Co raises 2022 revenue forecast to between $790 mln and
$810 mln, from prior guidance of $770 mln to $800 mln
    ** Also expects FY adj EPS in the range of $3.13 to $3.20,
up from $3.07 to $3.15 expected previously
    ** While RGEN saw a drop in COVID-related revenues in the
quarter, its base business recorded strong growth - co
    ** Stock down 9% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))